{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:07:04Z","timestamp":1789189624063,"version":"build-2803163510"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with relapsed or refractory (R\/R) lymphomas have benefited from chimeric antigen receptor (CAR)-T-cell therapy. However, this treatment is linked to a high frequency of adverse events (AEs), such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and hematologic toxicity. There has been increasing interest in hematological toxicity in recent years, as it can result in additional complications, such as infection or hemorrhage, which remain intractable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective, single-institution study to evaluate the patterns and outcomes of cytopenia following CAR-T-cell infusion and potential associated factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 133 patients with R\/R lymphoma who received CAR-T-cell therapy from June, 2017 to April, 2022 were included in this analysis. Severe neutropenia, anemia and thrombocytopenia occurred frequently (71, 30 and 41%, respectively) after CAR-T-cell infusion. A total of 98% of severe neutropenia and all severe thrombocytopenia cases occurred in the early phase. Early severe cytopenia was associated with CRS incidence and severity, as well as peak inflammatory factor (IL-6, C-reactive protein (CRP), and ferritin) levels. In multivariate analysis, prior hematopoietic stem cell transplantation (HSCT), baseline hemoglobin (HB), and lymphodepleting chemotherapy were independent adverse factors associated with early severe cytopenia. In addition, 18% and 35% of patients had late neutrophil- and platelet (PLT)-related toxicity, respectively. In multivariate analysis, lower baseline PLT count was an independent factor associated with late thrombocytopenia. More severe cytopenia was associated with higher infection rates and poorer survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This research indicates that improved selection of patients and management of CRS may help to decrease the severity of cytopenias and associated AEs and improve survival following CAR-T-cell therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:uri>https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03196830<\/jats:uri>, identifier NCT03196830.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.997589","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T15:35:56Z","timestamp":1662392156000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Jin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangping","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhi","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large b-cell lymphoma: Optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large b-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2019.10.8.9","article-title":"Axicabtagene ciloleucel: The first FDA-approved CAR T-cell therapy for Relapsed\/Refractory Large b-cell lymphoma","volume":"10","author":"King","year":"2019","journal-title":"J Adv Pract Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large b-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"20406207211017788","DOI":"10.1177\/20406207211017788","article-title":"The role of axicabtagene ciloleucel as a treatment option for patients with follicular\/marginal zone lymphoma","volume":"12","author":"Sandoval-Sus","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25445","article-title":"Toxicities of CD19 CAR-T cell immunotherapy","volume":"94","author":"Hirayama","year":"2019","journal-title":"Am J Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory Large b-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse Large b-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.702644","article-title":"New-onset severe cytopenia after CAR-T cell therapy: Analysis of 76 patients with relapsed or refractory acute lymphoblastic leukemia","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1697814","article-title":"Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)","volume":"61","author":"Nahas","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: A model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large b-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.664421","article-title":"A prospective investigation of bispecific CD19\/22 CAR T cell therapy in patients with relapsed or refractory b cell non-Hodgkin lymphoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Adv"},{"key":"B20","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3978\/j.issn.2218-676X.2013.07.03","article-title":"Hematopoietic stem cell senescence and cancer therapy-induced long-term bone marrow injury","volume":"2","author":"Shao","year":"2013","journal-title":"Transl Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01632-7","article-title":"Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large b cell lymphoma","volume":"57","author":"Galli","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.254045","article-title":"Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large b-cell lymphoma","volume":"106","author":"Strati","year":"2021","journal-title":"Haematologica"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory b cell malignancies: A phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2019.08.002","article-title":"Parallel comparison of 4-1BB or CD28 Co-stimulated CD19-targeted CAR-T cells for b cell non-hodgkin's lymphoma","volume":"15","author":"Ying","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory b-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large b cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.9.2431","article-title":"Infectious and immunosuppressive complications of purine analog therapy","volume":"13","author":"Cheson","year":"1995","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.521","article-title":"Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed Large b-cell lymphomas","author":"Ghilardi","year":"2022","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061501","article-title":"Cytopenia after CAR-T cell therapy-a brief review of a complex problem","volume":"14","author":"Sharma","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.997589\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T15:36:01Z","timestamp":1662392161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.997589\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2022.997589"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.997589","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]},"article-number":"997589"}}